Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Results from the RESCUE BT2 trial showed that among patients with mild or major strokes, more patients taking tirofiban had better 90-day outcomes than aspirin.
Read Full NewsPhase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.
Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.
Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.
Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.
1.
Chemotherapy Boosts Survival for Older Patients With TNBC
2.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
5.
Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test
1.
Consensus Recommendations for Healthy Hematologic Aging
2.
Exploring the Role of Fecal Leukocytes in Intestinal Health
3.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
4.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
5.
Clinical Pharmacology of Ferroptosis-Modulating Anticancer Pharmacotherapy
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Chemotherapy: What to Expect
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge